Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma

References

• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Bosch F, Lopez-Guillermo A, Campo E, Ribera J M, Conde E, Piris M A, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567–575
   PubMed Web of Science ®Google Scholar
• Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998; 34: 329–336
   PubMed Web of Science ®Google Scholar
• Freedman A S, Neuberg D, Gribben J G, Mauch P, Soiffer R J, Fisher D C, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16: 13–18
   PubMed Web of Science ®Google Scholar
• Vose J M, Bierman P J, Weisenburger D D, Lynch J C, Bociek Y, Chan W C, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000; 6: 640–645
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R M, Okoroji G J, Acholonu S A, Champlin R E. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003; 98: 2630–2635
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89: 1275–1276
   PubMed Web of Science ®Google Scholar
• Mangel J, Leitch H A, Connors J M, Buckstein R, Imrie K, Spaner D, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15: 283–290
   PubMed Web of Science ®Google Scholar
• Oinonen R, Jantunen E, Itala M, Lehtinen T, Kuittinen O, Franssila K, et al. Autologous stem cell transplantation in patients with mantle cell lymphoma. Leuk Lymphoma 2002; 43: 1229–1237
   PubMed Web of Science ®Google Scholar
• Ritchie D S, Seymour J F, Grigg A P, Roberts A W, Hoyt R, Thompson S, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007; 86: 101–105
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Gaillard F, Moreau P, Harousseau J L, Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 2005; 90: 1580–1582
   PubMed Web of Science ®Google Scholar
• Vandenberghe E, Ruiz de Elvira C, Loberiza F R, Conde E, Lopez-Guillermo A, Gisselbrecht C, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800
   PubMed Web of Science ®Google Scholar
• Haas R, Brittinger G, Meusers P, Murea S, Goldschmidt H, Wannenmacher M, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10: 1975–1979
   PubMed Web of Science ®Google Scholar
• de Guibert S, Jaccard A, Bernard M, Turlure P, Bordessoule D, Lamy T. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006; 91: 425–426
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992
   PubMed Web of Science ®Google Scholar
• Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107: 1014–1022
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257–262
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000; 18: 773–779
   PubMed Web of Science ®Google Scholar
• Howard O M, Gribben J G, Neuberg D S, Grossbard M, Poor C, Janicek M J, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–1294
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Conde E, Marco F, Caballero D, Arranz R, Lahuerta J J, Sureda A, et al. Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL) [abstract]. Blood 2002; 100: 2529a
   Google Scholar
• Vose J, Loberiza F R, Bierman P J, Bociek G, Armitage J O. Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High dose methotrexate and cytarabine (M-C) (± rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol 2006; 24: 7511a
   Google Scholar
• E S Jaffe, Harris, N L, Stein, H, Vardiman, J. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press. 2001
   Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 2454–2460
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard E M, Moullet I, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8: 701–704
   PubMed Web of Science ®Google Scholar
• Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kroger N, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1: 87–94
   PubMedGoogle Scholar
• Gianni A M, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749–755
   PubMed Web of Science ®Google Scholar
• Kasamon Y L, Jones R J, Diehl L F, Nayer H, Borowitz M J, Garrett-Mayer E, et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005; 11: 39–46
   PubMed Web of Science ®Google Scholar
• Ganti A K, Bierman P J, Lynch J C, Bociek R G, Vose J M, Armitage J O. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16: 618–624
   PubMed Web of Science ®Google Scholar
• Andersen N S, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003; 71: 73–80
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet A S, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104: 1434–1441
   PubMed Web of Science ®Google Scholar
• Gopal A K, Rajendran J G, Petersdorf S H, Maloney D G, Eary J F, Wood B L, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158–3162
   PubMed Web of Science ®Google Scholar